Stockscreener 앱 받기
6.23
1.58%
-0.10
전일 마감가:
$6.33
열려 있는:
$6.36
하루 거래량:
264.20K
Relative Volume:
0.48
시가총액:
$202.61M
수익:
-
순이익/손실:
$-29.25M
주가수익비율:
-5.253
EPS:
-1.186
순현금흐름:
$-22.80M
1주 성능:
-2.50%
1개월 성능:
-29.37%
6개월 성능:
-27.64%
1년 성능:
+37.22%
1일 변동 폭
$6.225
$6.515
1주일 범위
$5.95
$6.5773
52주 변동 폭
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
명칭
Sagimet Biosciences Inc
전화
(650) 561-8600
주소
155 BOVET RD., SUITE 303, SAN MATEO
SGMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.23 | 205.86M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 개시 | Wedbush | Outperform |
| 2025-08-07 | 재개 | H.C. Wainwright | Buy |
| 2025-07-24 | 개시 | Canaccord Genuity | Buy |
| 2024-12-06 | 개시 | Oppenheimer | Outperform |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-06-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-05-02 | 개시 | H.C. Wainwright | Buy |
| 2024-03-25 | 개시 | Leerink Partners | Outperform |
| 2023-08-08 | 개시 | Goldman | Buy |
| 2023-08-08 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-08 | 개시 | Piper Sandler | Overweight |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
모두보기
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
What drives Sagimet Biosciences Inc stock priceStock Split Announcements & High Yield Portfolio Picks - earlytimes.in
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat - TipRanks
Sagimet's license partner Ascletis announced acceptance of new drug application for Denifanstat - marketscreener.com
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration - The Manila Times
Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative
Sagimet’s License Partner Ascletis Announced Acceptance of - GlobeNewswire
Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A significant driver of top-line growth: Sagimet Biosciences Inc (SGMT) - Setenews
Is Sagimet Biosciences Inc. (0O2) stock worth holding before Fed meetingQuarterly Risk Review & Daily Risk Controlled Trade Plans - Newser
Is Sagimet Biosciences Inc. (0O2) stock prepared for digital transitionWeekly Trade Analysis & Low Risk High Reward Trade Ideas - Newser
How Sagimet Biosciences Inc. (0O2) stock trades after earningsTrade Ideas & Verified Technical Trade Signals - Newser
How cyclical is Sagimet Biosciences Inc. (0O2) stock compared to rivalsJuly 2025 WrapUp & Accurate Trade Setup Notifications - Newser
Is Sagimet Biosciences Inc. (0O2) stock a buy during volatile markets2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Why Sagimet Biosciences Inc. (0O2) stock stays undervaluedCEO Change & Entry Point Strategy Guides - Newser
How resilient is Sagimet Biosciences Inc. stock in market downturnsEarnings Miss & High Return Trade Opportunity Guides - Newser
Will Sagimet Biosciences Inc. stock benefit from commodity prices2025 Market Outlook & Real-Time Market Trend Scan - Newser
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Sagimet Biosciences executive chairman sells $290k in shares By Investing.com - Investing.com Australia
Insider Selling: Sagimet Biosciences (NASDAQ:SGMT) Chairman Sells 37,688 Shares of Stock - MarketBeat
Insider Sell: George Kemble Sells Shares of Sagimet Biosciences Inc (SGMT) - GuruFocus
Sagimet Biosciences executive chairman sells $290k in shares - Investing.com
Will Sagimet Biosciences Inc. (0O2) stock sustain bullish trend into 2025Weekly Stock Recap & AI Enhanced Market Trend Forecasts - newser.com
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - The Manila Times
Sagimet Biosciences Inc. to Participate in 8th Annual Evercore ISI Healthcare Conference on December 2, 2025 - Quiver Quantitative
Why Sagimet Biosciences Inc. (0O2) stock attracts wealthy investorsMarket Risk Summary & Growth Focused Investment Plans - newser.com
Can Sagimet Biosciences Inc. (0O2) stock attract analyst upgradesPortfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
What catalysts could drive Sagimet Biosciences Inc. stock higherPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
Detecting support and resistance levels for Sagimet Biosciences Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com
Sagimet Biosciences Inc (0O2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
How sustainable is Sagimet Biosciences Inc. stock dividend payoutJuly 2025 Short Interest & Safe Capital Allocation Plans - newser.com
Identifying reversal signals in Sagimet Biosciences Inc.Rate Cut & Fast Exit and Entry Trade Guides - newser.com
Reversal indicators forming on Sagimet Biosciences Inc. stockWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
Published on: 2025-11-19 02:00:25 - newser.com
Sagimet Biosciences Inc (SGMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):